This Research Topic is part of a series with:
Chronic Inflammation and Pharmacological Interventions in Cardiovascular DiseasesCardiovascular diseases (CVDs) are a group of complex and multifactorial disorders, and their pathogenesis is still not completely understood. It is recognized that inflammation, especially the chronic inflammation is a common pathogenesis of many CVDs, such as atherosclerosis, myocardial infarction and stroke. Continuous inflammation causes a series of pathological changes of hearts and blood vessels. Clinical trials and basic studies have shown that inflammatory inhibition by pharmacological and other interventions can markedly reduce the degree of pathological changes of hearts or blood vessels, and decrease the morbidity and mortality of CVD events. Thus, the advance of therapies directly or indirectly modulating chronic inflammation is an important approach for prevention and treatment of CVDs.
Pharmacological interventions are the primary therapeutic approaches for CVDs. In the past few decades, plenty of drugs for different targets including anti-inflammatory agents have been developed and used to prevent and treat different CVDs in the clinic. In the past few years, the flood of new drugs including chemical-based drugs and natural herbal products have provided more choices to the treatment of CVDs. Recently, biotherapies and molecular targeted therapies utilizing cell-based products such as stem cells, immune cells, exosomes, cytokines, peptides and monoclonal antibodies have also been used to treat CVDs, and some of them specifically target at inflammation. The purpose of this Research Topic is to provide potential readers with new advances on prevention and treatment of CVDs, especially on the new therapies targeting chronic inflammation.
This Research Topic welcomes submissions of Original Research Articles, Reviews, and other types of articles related to cellular and molecular mechanisms of chronic inflammation in pathogenesis of CVDs, as well as novel pharmacological and biological therapies for diagnosis, prevention and treatment of CVDs. The potential subtopics are related, but not limited to the following areas:
• Cellular and molecular mechanisms underlying the role of inflammation in genesis and development of CVDs.
• Therapeutic effects of clinical medicine and natural products on prevention and improvement of CVDs by intervention of cardiovascular inflammation.
• Biotherapies such as stem cell and immune cell transplantations, and applications of exosomes, cytokines, peptides and monoclonal antibodies for treatment of CVDs and chronic inflammation.
• Other new approaches and diagnosis methods for CVDs.
